Abstract: Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of angiogenesis-related medical conditions such as cancer and cancer metastases are also disclosed.

Abstract: Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of angiogenesis-related medical conditions such as cancer and cancer metastases are also disclosed.

Abstract: An ex-vivo method for the early diagnosis of minimal hepatic encephalopathy by means of determining serum 3-nitrotyrosine relates to an ex-vivo method for the detection and early diagnosis of minimal hepatic encephalopathy (MHE) in patients with liver diseases, including cirrhosis, based on the presence of specific serum biomarkers, specifically by means of determining 3-nitrotyrosine (3-NT), which comprises obtaining serum or plasma obtained from the blood of patients and controls, and determining whether or not the measurement of the concentration of 3-nitrotyrosine obtained is greater than a specific level.

Abstract: Compounds to be used in the treatment of diseases based on the expression of toxic transcripts. The present invention relates to peptide molecules, specifically hexapeptides, designed for the prevention and/or treatment of diseases the etiology whereof is based on the presence of toxic transcripts that comprise CUG, CCUG, CGG, CAG and AAG repeats, preferably: DM1 SCA8, DM2, FXTAS, HD and FA.